Hyaluronidase: The Reversal Agent Every Injector Must Be Ready to Use
Hyaluronidase is the only reason hyaluronic acid holds its position as the default facial filler. Every other property — the rheology, the longevity, the tissue integration — matters less than the simple fact that a mistake can be undone. That safety net is only real, however, if the injector can use it decisively at the moment it is needed, which is usually the worst possible moment to be reading a protocol for the first time.
This article covers the two clinical situations that call for hyaluronidase, the doses that belong to each, and the cases where dissolving is the wrong answer.
Two situations, two completely different doses
The single most common error is treating hyaluronidase as one intervention with one dose. It is not. A vascular occlusion and a slightly overfilled tear trough are different emergencies — one of them is not an emergency at all — and the amount of enzyme, the speed of the response and the endpoint are all different.
Aesthetic correction — a nodule, a Tyndall effect under thin skin, an asymmetry, a migration that will not settle. There is no time pressure. Conservative quantities, placed precisely, reassessed after two weeks. Starting low matters here because hyaluronidase does not distinguish between the filler you injected and the patient's own hyaluronic acid in the surrounding tissue; overshooting produces a hollow that takes months to recover.
Vascular occlusion — the filler has entered or compressed a vessel and tissue is losing its blood supply. Everything changes. Dose is high, delivery is flooding rather than precise, and the intervention repeats until perfusion returns. Hesitancy here costs tissue.
Recognising an occlusion early
The classical picture is immediate, disproportionate pain and blanching along a vascular territory, followed within hours by a dusky, reticulated mottling that does not blanch under pressure and a delayed capillary refill. In practice the presentation is often less obliging: pain may be modest, particularly after generous local anaesthesia, and the early skin change can be mistaken for ordinary post-injection erythema [2].
The clinically useful habit is to treat asymmetry as the alarm. Colour change confined to one vascular territory, on one side, that does not match the other side after an identical injection, is an occlusion until proven otherwise. Waiting to be certain is how a recoverable event becomes necrosis.
The high-dose pulsed protocol
The approach that changed outcomes in this field is high-dose, repeated and generous with its territory. The principles are what follow; the figures are deliberately not, because they vary with the preparation licensed in each country and belong in the protocol your clinic works to — agreed with your medical lead and reviewed against the current guidance, not learned from an article:
- Flood the entire ischaemic territory, not the injection point. The filler bolus is somewhere in a vessel that may run well beyond where the needle went. Treating only where you injected treats the wrong place.
- The quantity used is far larger than anything used for aesthetic correction. Intuitions carried over from dissolving a nodule are the wrong scale here — this is why the figure must come from a current protocol, not from memory.
- Treatment is repeated at intervals until capillary refill, colour and pain normalise. A single administration is a start, not a treatment.
- Do not stop because some improvement appeared. Partial reperfusion is an argument for the next dose, not for going home.
- Hyaluronidase diffuses well through tissue planes, which is what makes flooding viable — but it cannot reach what it cannot reach; intra-arterial technique is not required and should not be attempted.
Adjuncts vary between protocols and are not equivalent to one another. Warmth and massage appear in current guidance alongside the enzyme; aspirin appears in several protocols by extrapolation from other ischaemic settings. Topical nitroglycerin belongs in a separate category: published guidance, including the CMAC guideline, advises against it, on evidence that it may worsen perfusion by propagating product distally. None of these substitutes for adequate, repeated hyaluronidase, and none should delay it. Any suspicion of visual symptoms is a different emergency again: immediate referral to ophthalmology, because retinal ischaemia has a window measured in minutes to a couple of hours and is not managed from an aesthetic clinic [1].
Allergy, and the test that does not settle much
Hyaluronidase preparations are derived from animal or recombinant sources and hypersensitivity, while uncommon, is real — ranging from local swelling and erythema to true anaphylaxis. The traditional intradermal test dose remains contested: it delays treatment, and a negative test does not exclude a reaction to a much larger dose given later.
A defensible position, and the one most emergency protocols now take, is that in a genuine vascular occlusion the risk of withholding treatment exceeds the risk of a reaction — so you treat, with resuscitation equipment and adrenaline immediately to hand. In elective correction, where nothing is time-critical, testing is reasonable and costs nothing but a delay. Either way, the clinic must be equipped to manage anaphylaxis before it stocks the enzyme at all [3].
When dissolving is the wrong call
Three situations account for most of the misuse:
The filler is not hyaluronic acid. Hyaluronidase does nothing to poly-L-lactic acid, calcium hydroxylapatite, polymethylmethacrylate or silicone. Injecting it into a complication caused by one of these adds a second intervention without removing the first. This is precisely why a proper record of what was injected, when and where — including work done elsewhere — belongs in every set of notes.
The patient is unhappy but the result is not wrong. Dissolving on demand, days after treatment, before swelling has settled, is a common route to a worse outcome. Most early dissatisfaction is oedema. Two weeks of reassurance is a legitimate treatment.
An inflammatory nodule of uncertain origin. A late, tender, warm nodule may be a delayed inflammatory reaction or infection rather than a placement problem, and reaching for hyaluronidase first can delay the antibiotic or the biopsy that the patient actually needed.
What preparedness actually looks like
Owning a vial is not a protocol. A clinic that is genuinely ready has the enzyme in date and in the room where injecting happens, a written dosing plan that does not require a search at the moment of need, anaphylaxis equipment and the training to use it, a colleague or referral route reachable by phone, and an ophthalmology pathway agreed in advance rather than improvised.
If a training course teaches filler placement without also teaching this, it has taught half the procedure. The techniques that produce beautiful results and the techniques that cause occlusions are the same techniques — the difference is what happens in the twenty minutes afterwards.